(Reuters) - Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins.
The deal gives Arrowhead the freedom to operate in any target for any indication, strengthening the belief that RNAi therapeutics is a bilateral field - there's Alnylam and there's Arrowhead, Chief Executive Christopher Anzalone told Reuters.
Also read: California To Give Health Clinics $20 Million To Counter Possible Trump Cuts
Read more